Incorporating digitally derived endpoints within clinical development programs by leveraging prior work
- PMID: 37563201
- PMCID: PMC10415378
- DOI: 10.1038/s41746-023-00886-9
Incorporating digitally derived endpoints within clinical development programs by leveraging prior work
Abstract
Digital health technologies (DHTs) enable remote data collection, support a patient-centric approach to drug development, and provide real-time data in real-world settings. With increasing use of DHTs in clinical care and development, we expect a growing body of evidence supporting use of DHTs to capture endpoint data in clinical trials. As the body of evidence grows, it will be critical to ensure that available prior work can be leveraged. We propose a framework to reuse analytical and clinical validation, as well as verification data, generated for existing DHTs. We apply real life case studies to illustrate our proposal aimed at leveraging prior work, while applying the V3 framework (verification, analytical validation, clinical validation) and avoiding duplication. Utilizing our framework will enable stakeholders to share best practices and consistent approaches to employing these tools in clinical studies, build on each other’s work, and ultimately accelerate evidence generation demonstrating the reproducibility and value add of these new tools.
Conflict of interest statement
The authors declare no competing non-financial interests but the following competing financial interests. R.A. is an employee and shareholder of Regeneron. I.B. and R.K. are employees and shareholders of F. Hoffmann-La Roche. M.K.D. is an employee and shareholder of Amgen. D.F. is an employee and shareholder of Janssen. L.O. is an employee and shareholder of Biogen. I.K. and H.-P.P. are employees and shareholders of Bayer. A.B., F.K., and S.R. are employees of Bayer. The views in this publication are that of the authors and do not express the position of our respective companies on the topics discussed.
Figures




References
-
- U.S. Food and Drug Administration. Draft Guidance for Industry: Investigators, and Other Stakeholders. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (2021) Guidance for Industry (fda.gov).
LinkOut - more resources
Full Text Sources
Research Materials